TG Therapeutics reports positive Phase 3 trial for single-dose BRIUMVI in multiple sclerosis

Filed May 27, 2026 · Period ending May 27, 2026 · ~1 min read

Key Changes

• high

  Phase 3 ENHANCE trial met endpoints testing a consolidated single infusion regimen of BRIUMVI for relapsing MS, potentially simplifying treatment from the current multi-dose schedule and improving patient convenience.

  Item 8.01 verify on EDGAR →
• high

  Positive topline results could support regulatory submissions for label expansion, potentially broadening commercial opportunity for the company's approved MS therapy.

  Press Release verify on EDGAR →
• medium

  BRIUMVI is already approved for relapsing forms of MS; this trial tests an improved dosing regimen rather than a new indication or drug candidate.

  Item 8.01 verify on EDGAR →